Next-gen IL-13 dermatology assets command this deal value

The approaching biosimilar competition for first-generation dermatology biologics (adalimumab biosimilars already launched, dupilumab patent cliff approaching) is reshaping the dermatology deal landscape. Next-generation IL-13 and IL-4Ra inhibitors with improved dosing convenience, better efficacy, or expanded indication packages are commanding premium deal terms. Phase 2 IL-13 deals for AD average $2.4B total value, as licensees seek differentiated assets to defend against biosimilar erosion.

Based on analysis of 600+ biopharma licensing deals from 2020-2026